<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806453</url>
  </required_header>
  <id_info>
    <org_study_id>ALNEO1</org_study_id>
    <nct_id>NCT02806453</nct_id>
  </id_info>
  <brief_title>Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinico Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Hospital</source>
  <brief_summary>
    <textblock>
      A randomized controlled cross-over trial in full-term infants affected by symptoms suggestive
      of GER, evaluated through a validated questionnaire (Infant Gastroesophageal Reflux
      Questionnaire Revised).

      The parents of all of the enrolled infants will be reassured on the benign nature of the
      condition and will advise to apply lifestyle changes for one week.

      Than, the patients will be randomized into one of the two sequence treatment groups. (group
      A: Mg alginate/thickened formula; group B: thickened formula/Mg alginate) for two weeks.
      Evaluation of symptom scores will be performed at day 0, day 7, day 21 and day 35.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of symptom scores</measure>
    <time_frame>From day 0 to day 35</time_frame>
    <description>Infant Gastroesophageal Reflux Questionnaire Revised</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: Mg alginate/thickened formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: thickened formula/Mg alginate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>thickened formula</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mg alginate</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>reassurance with lifestyle changes</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  full-term ages 3 to 12 months, affected by symptoms suggestive of GER.

          -  infant regurgitation defined according to the Rome IV criteria

          -  informed consent

        Exclusion Criteria:

          -  Evidence of chronic diseases, hepatic, renal, or cardiac diseases, metabolic or
             central nervous system diseases, or use of acid suppressor treatment (H2-receptor
             antagonists or proton pump inhibitors [PPIs]), thickened formula, or a history of
             prematurity or atopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept Of Obstetrics and Neonatology - Section of Neonatology University of Bari Policlinico Hospital</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Maria Elisabetta Baldassarre</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alginic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

